Phase II evaluation of carboplatin in advanced endometrial carcinoma

H. J. Long, D. M. Pfeifle, H. S. Wieand, J. E. Krook, J. H. Edmonson, Jan Craig Buckner

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Carboplatin was administered by iv bolus every 28 days to 26 patients who had extensive metastatic or recurrent endometrial adenocarcinoma and no prior chemotherapy exposure. The dose level was 400 mg/m2 in 5 patients with and 4 patients without prior irradiation and 300 mg/m2 in 16 patients with prior pelvic irradiation. Partial disease regressions were seen in 28% of patients (95% confidence interval, 12%-50%), with a median response duration of 129 days. Median survival of all patients was 215 days; median time to disease progression for all patients was 117 days. We conclude that carboplatin is an active agent in advanced endometrial carcinoma and is worthy of further investigation in single-agent and combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)276-278
Number of pages3
JournalJournal of the National Cancer Institute
Volume80
Issue number4
StatePublished - 1988

Fingerprint

Chemotherapy
Carboplatin
Endometrial Neoplasms
Irradiation
Evaluation
Progression
Confidence interval
Dose
Regression
Partial
Combination Drug Therapy
Disease Progression
Adenocarcinoma
Confidence Intervals
Drug Therapy
Survival
Median

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging

Cite this

Long, H. J., Pfeifle, D. M., Wieand, H. S., Krook, J. E., Edmonson, J. H., & Buckner, J. C. (1988). Phase II evaluation of carboplatin in advanced endometrial carcinoma. Journal of the National Cancer Institute, 80(4), 276-278.

Phase II evaluation of carboplatin in advanced endometrial carcinoma. / Long, H. J.; Pfeifle, D. M.; Wieand, H. S.; Krook, J. E.; Edmonson, J. H.; Buckner, Jan Craig.

In: Journal of the National Cancer Institute, Vol. 80, No. 4, 1988, p. 276-278.

Research output: Contribution to journalArticle

Long, HJ, Pfeifle, DM, Wieand, HS, Krook, JE, Edmonson, JH & Buckner, JC 1988, 'Phase II evaluation of carboplatin in advanced endometrial carcinoma', Journal of the National Cancer Institute, vol. 80, no. 4, pp. 276-278.
Long, H. J. ; Pfeifle, D. M. ; Wieand, H. S. ; Krook, J. E. ; Edmonson, J. H. ; Buckner, Jan Craig. / Phase II evaluation of carboplatin in advanced endometrial carcinoma. In: Journal of the National Cancer Institute. 1988 ; Vol. 80, No. 4. pp. 276-278.
@article{4ac0bca148c843fca1a6bb1a9697b43b,
title = "Phase II evaluation of carboplatin in advanced endometrial carcinoma",
abstract = "Carboplatin was administered by iv bolus every 28 days to 26 patients who had extensive metastatic or recurrent endometrial adenocarcinoma and no prior chemotherapy exposure. The dose level was 400 mg/m2 in 5 patients with and 4 patients without prior irradiation and 300 mg/m2 in 16 patients with prior pelvic irradiation. Partial disease regressions were seen in 28{\%} of patients (95{\%} confidence interval, 12{\%}-50{\%}), with a median response duration of 129 days. Median survival of all patients was 215 days; median time to disease progression for all patients was 117 days. We conclude that carboplatin is an active agent in advanced endometrial carcinoma and is worthy of further investigation in single-agent and combination chemotherapy.",
author = "Long, {H. J.} and Pfeifle, {D. M.} and Wieand, {H. S.} and Krook, {J. E.} and Edmonson, {J. H.} and Buckner, {Jan Craig}",
year = "1988",
language = "English (US)",
volume = "80",
pages = "276--278",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Phase II evaluation of carboplatin in advanced endometrial carcinoma

AU - Long, H. J.

AU - Pfeifle, D. M.

AU - Wieand, H. S.

AU - Krook, J. E.

AU - Edmonson, J. H.

AU - Buckner, Jan Craig

PY - 1988

Y1 - 1988

N2 - Carboplatin was administered by iv bolus every 28 days to 26 patients who had extensive metastatic or recurrent endometrial adenocarcinoma and no prior chemotherapy exposure. The dose level was 400 mg/m2 in 5 patients with and 4 patients without prior irradiation and 300 mg/m2 in 16 patients with prior pelvic irradiation. Partial disease regressions were seen in 28% of patients (95% confidence interval, 12%-50%), with a median response duration of 129 days. Median survival of all patients was 215 days; median time to disease progression for all patients was 117 days. We conclude that carboplatin is an active agent in advanced endometrial carcinoma and is worthy of further investigation in single-agent and combination chemotherapy.

AB - Carboplatin was administered by iv bolus every 28 days to 26 patients who had extensive metastatic or recurrent endometrial adenocarcinoma and no prior chemotherapy exposure. The dose level was 400 mg/m2 in 5 patients with and 4 patients without prior irradiation and 300 mg/m2 in 16 patients with prior pelvic irradiation. Partial disease regressions were seen in 28% of patients (95% confidence interval, 12%-50%), with a median response duration of 129 days. Median survival of all patients was 215 days; median time to disease progression for all patients was 117 days. We conclude that carboplatin is an active agent in advanced endometrial carcinoma and is worthy of further investigation in single-agent and combination chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0023938703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023938703&partnerID=8YFLogxK

M3 - Article

C2 - 3280811

AN - SCOPUS:0023938703

VL - 80

SP - 276

EP - 278

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -